论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Yu H, Pan J, Guo Z, Yang C, Mao L
Received 28 August 2018
Accepted for publication 22 November 2018
Published 3 January 2019 Volume 2019:12 Pages 391—395
DOI https://doi.org/10.2147/OTT.S185556
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Sanjay Singh
Abstract: In recent
years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive
immunotherapy has received great attention and made great breakthroughs. CAR-T
cells show great specificity, targeting, and less major histocompatibility
complex restriction in tumor immunotherapy, significantly different from
traditional T cells. In spite of the progress of CART-T technology in the treatment
of lymphoma, leukemia, and other blood system tumor, there are still many
difficulties in the treatment of solid tumors by CAR-T technology. In this
review, we will make a brief summary of the present situation of CAR-T cells in
the treatment of prostate cancer, and discuss the promise of the application of
this technology to prostate cancer therapy.
Keywords: prostate
cancer, CAR-T cells, adoptive immunotherapy, review
